Descripción del proyecto
Un péptido quimérico clave para el tratamiento de las enfermedades de Alzheimer y Parkinson
Las enfermedades de Alzheimer y Parkinson son trastornos neurológicos provocados por el deterioro de las neuronas. En la carrera por encontrar una cura, los ensayos clínicos basados en inmunoterapias contra placas amiloides no han tenido éxito. El proyecto financiado con fondos europeos AmInnovation desarrolló una nueva solución: AmyP53, un compuesto revolucionario que puede bloquear el primer paso de estas enfermedades. Su objetivo era eliminar el riesgo de AmyP53 mediante la evaluación de su seguridad en animales. Durante el proyecto, se sintetizó este fármaco con potencial terapéutico, se caracterizaron sus propiedades químicas y biológicas y se administró por vía intravenosa e intranasal a ratas macho y hembra. Tal y como se esperaba, los resultados fueron excepcionales y no revelaron ningún problema de toxicidad, lo que sin duda posibilitará muy pronto iniciar los primeros ensayos en humanos.
Objetivo
Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong.
AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate.
AmyPore solution, called “AmyP53” is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases.
As a matter of fact, relying upon :
- an exclusive license, linked to an international patent owned by the inventors,
- recent scientific publications,
- and additional recent conclusive tests,
AmyP53 is :
- easy to test,
- easy to produce worldwide,
- easy to administer.
AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.
Ámbito científico
Not validated
Not validated
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicineneurologyparkinson
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
13240 SEPTEMES-LES-VALLONS
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.